Copaxone is indicated for the reduction in frequency of relapses in ambulatory patients,
e. who can walk unaided) with relapsing,
remitting multiple sclerosis (MS) characterised by at least two attacks of neurological dysfunction over the preceding two-year period.
Copaxone is not indicated in primary or
secondary progressive MS.